Objective
Inflammation is an integral part of carcinogenesis. Several different cells of myeloid, lymphoid and non-hematopoietic origin contribute to the strong link between cancer and inflammation and maintain a pro-tumoral environment. The complexity of this environment and the diversity of tumours lead to distinct responses during tumour immunotherapies. Nucleic acid-sensing (NAS) TLR ligands are an essential component of anti-tumour strategies to induce efficient tumour-specific adaptive immune responses. NAS TLRs can also detect nucleic acid released during tumour necrosis, thereby modulating the tumour microenvironment. Interestingly, NAS TLR signalling can induce cell death via apoptosis or induce pro-tumoral survival and proliferation of cancer cells. These opposing effects of NAS TLR ligands may be due to the differential response of distinct tumour-associated cells to TLR ligands. Indeed, the individual response of subsets of tumour-associated cells remains unclear, thus making it difficult to predict the outcome of tumour immunotherapies. Furthermore, the expression and regulation of NAS TLRs in tumour-associated cells remains unknown. Using ex vivo cultures from adenocarcinomas and melanomas, we will systematically analyze the expression of all NAS TLRs on sorted cells. Using cutting edge technologies, we will dissect the role of TLRs in modulating the tumour microenvironment, which will provide novel insights into our ability to modulate cellular inflammation in the tumour. This proposal has the potential not only to reveal novel aspects of NAS TLR regulation, but also to provide new targets for the modulation of the tumour stroma and the infiltrating cells during carcinogenesis.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology prostate cancer
- natural sciences biological sciences biochemistry biomolecules nucleic acids
- medical and health sciences clinical medicine oncology skin cancer melanoma
- medical and health sciences clinical medicine oncology breast cancer
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2014
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
OX1 2JD Oxford
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.